06 Jan 2026 1 min read BiQ Journal

BiQ Journal: Quick Comparison of WVE-007 vs ARO-INHBE (01/06/26) (WVE ARWR)

Many of the companies discussed in the BiQ Journal are early-stage and/or may not meet the criteria for the BiQ Active Portfolio (BiQAP). The BiQ Journal is for information purposes only and does not constitute a complete analysis of any companies mentioned. Nothing presented herein should be considered investment advice. I may or may not have positions in the companies mentioned and may open or close positions at any time.

We received positive data from ARWR today for its INHBE and ALK7 programs. Below is a quick side-by-side comparison of results from WVE-007 and ARO-INHBE. Note that the data for WVE-007 included 8x as many patients, at a lower dose, in a healthier population, and with an earlier data cutoff.

Still, strong PoC data for both WVE-007 and ARO-INHBE, which also reconfirms potential use in both combination and maintenance settings.

I have excluded ARO-ALK7 data for now.

I am long WVE (BiQ ACB $11.60) in my personal speculative portfolio.

Not a BiQ Premium member, or have a friend who may be interested? Try BiQ Premium for $50 per month, or $375 (25% off) for the first year.

Biotech iQ is 100% subscriber supported. If you find this information helpful, please spread the word. You can also follow me on X @ Biotech iQ (_Biotech_iQ).

Biotech iQ is not an investment professional, and nothing on this page or this website should be considered investment advice. Please consult with a licensed investment professional as necessary. Past performance is not indicative of future results.